Medicines: new game, new rules - Pathways to better and affordable medicines

Thursday, 5 October 2017 | 9.00-11.30 | Room 1

Organised by Open Society Foundations in cooperation with European Public Health Alliance (EPHA) and European Public Health Association (EUPHA)

2016 was a year of political recognition that imbalances exist in the pharmaceutical system along with widespread concerns about the sustainability of healthcare systems in Europe. The price of both old and new medicines has been rising dramatically, leading to rationing of medicines for patients and other access to treatment challenges. These problems are the result of a dysfunctional R&D system that  prioritises profits over public health imperatives and individual patients’ needs.

This session will respond to the calls by EU and national policy-makers for actionable policy recommendations. It will articulate a set of short, mid and long-term policy proposals in the area of incentives for drug development and the need for public health needs-driven regulatory reform in Europe, to guarantee genuine therapeutic advance for the benefit of all patients.

F5 Programme PDF

Speakers & panellists

Welcome & introductory remarks

KITI KAJANA PHILLIPS, Program Officer, Access to Medicines & Innovation, Public Health Program, Open Society Foundations (OSF)

Panel I – Do we get the medicines we need and can afford?

Interventions from:

SUERIE MOON, Director of Research at the Global Health Centre, Graduate Institute of International and Development Studies, Geneva; and Adjunct Lecturer on Global Health at the Harvard T.H. Chan School of Public Health

COURTNEY DAVIS, Director of the Masters in Medicine, Health and Public Policy, Department of Global Health and Social Medicine, Kings College London

AJAY AGGARWAL, Consultant clinical oncologist, Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine

LIVIO GARATTINI, Director, Angelo & Angela Valenti - Centre of Health Economics (CESAV), Mario Negri Institute, Italy


DEBORAH COHEN, Associate Editor, British Medical Journal (BMJ)

Panel II - The access to medicines problems in Europe: What can governments do?

Interventions from

MARCEL VAN RAAIJ, Director Medicines & Medical Technology, Ministry of Health, Welfare and Sport, The Netherlands

CLEMENS MARTIN AUER, Director General, Federal Ministry of Health & Women's Affairs, Austria

MELANIE KENNEDY, Patient Advocate, Just Treatment, UK

MARTIN MUNTE, President, Pharmig - Association of the Austrian Pharmaceutical Industry; and Chief Executive Officer, Amgen

YANNIS NATSIS, Policy Manager, Universal Access & Affordable Medicines, European Public Health Alliance (EPHA)


MARTIN MCKEE, Professor, London School of Hygiene and Tropical Medicine

Concluding remarks

YANNIS NATSIS, Policy Manager, Universal Access & Affordable Medicines, European Public Health Alliance (EPHA)

Biographical information

NameAuer, Clemens Martin
CVDownload PDF
NameAggarwal, Ajay
CVDownload PDF
NameCohen, Deborah
CVDownload PDF
NameDavis, Courtney
CVDownload PDF
PresentationDownload PDF
NameGarattini, Livio
CVDownload PDF
NameKajana-Phillips, Kiti
CVDownload PDF
NameKennedy, Melanie
CVDownload PDF
NameMcKee, Martin
CVDownload PDF
NameMoon, Suerie
CVDownload PDF
NameMunte, Martin
CVDownload PDF
NameNatsis, Yannis
CVDownload PDF
Namevan Raaij, Marcel
CVDownload PDF



View complete photo collection

/latest update 12.10. md/

EHFG News & Updates

EHFG Headquarters

EHFG Vienna Office

VAT No. ATU44155007 Bank Data:
IBAN AT 152040400200222240 
Bank Salzburger Sparkasse
Kurgartenstraße, 5630 Bad Hofgastein, Austria